Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James L Riley

Showing results (111-120 of 127) with videos related to

Pageof 13
Sort By:
Blood|November 14, 2015
Umbilical cord blood-derived T regulatory cells to prevent GVHD: kinetics, toxicity profile, and clinical effectClaudio G Brunstein, Jeffrey S Miller, David H McKenna, et al.
Plos Pathogens|November 18, 2016
Potent and Broad Inhibition of HIV-1 by a Peptide from the gp41 Heptad Repeat-2 Domain Conjugated to the CXCR4 Amino TerminusGeorge J Leslie, Jianbin Wang, Max W Richardson, et al.
Human Gene Therapy|January 31, 2013
Efficient clinical scale gene modification via zinc finger nuclease-targeted disruption of the HIV co-receptor CCR5Dawn A Maier, Andrea L Brennan, Shuguang Jiang, et al.
Nature Medicine|November 11, 2008
Control of HIV-1 immune escape by CD8 T cells expressing enhanced T-cell receptorAngel Varela-Rohena, Peter E Molloy, Steven M Dunn, et al.
Biorxiv : the Preprint Server for Biology|February 6, 2026
The ancestral haplotype of P2RX5 yields a B-cell surface marker and a multi-lineage immunotherapy targetZhiwei Ang, Annette Castro, Luca Paruzzo, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|January 11, 2026
Clinical Trial Results Provide the Rationale to Protect Dual HIV-specific T Cells with a Signaling-Defective HIV Fusion InhibitorPablo Tebas, Julie K Jadlowsky, Yuqi Zhou, et al.
Nature Biotechnology|July 1, 2008
Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleasesElena E Perez, Jianbin Wang, Jeffrey C Miller, et al.
Nature Biomedical Engineering|October 21, 2025
CCR5-targeted allogeneic gamma-delta CD19 chimeric antigen receptor T cells for HIV-associated B cell-malignancy immunotherapyÁngel Ramírez-Fernández, Alexander J Dimitri, Fang Chen, et al.
Plos Pathogens|May 3, 2011
Engineering HIV-resistant human CD4+ T cells with CXCR4-specific zinc-finger nucleasesCraig B Wilen, Jianbin Wang, John C Tilton, et al.
The Journal of Clinical Investigation|February 11, 2021
CCR5-edited CD4+ T cells augment HIV-specific immunity to enable post-rebound control of HIV replicationPablo Tebas, Julie K Jadlowsky, Pamela A Shaw, et al.
Pageof 13

Showing results (111-120 of 127) with videos related to

Sort By:
Pageof 13
Blood|November 14, 2015
Umbilical cord blood-derived T regulatory cells to prevent GVHD: kinetics, toxicity profile, and clinical effectClaudio G Brunstein, Jeffrey S Miller, David H McKenna, et al.
Plos Pathogens|November 18, 2016
Potent and Broad Inhibition of HIV-1 by a Peptide from the gp41 Heptad Repeat-2 Domain Conjugated to the CXCR4 Amino TerminusGeorge J Leslie, Jianbin Wang, Max W Richardson, et al.
Human Gene Therapy|January 31, 2013
Efficient clinical scale gene modification via zinc finger nuclease-targeted disruption of the HIV co-receptor CCR5Dawn A Maier, Andrea L Brennan, Shuguang Jiang, et al.
Nature Medicine|November 11, 2008
Control of HIV-1 immune escape by CD8 T cells expressing enhanced T-cell receptorAngel Varela-Rohena, Peter E Molloy, Steven M Dunn, et al.
Biorxiv : the Preprint Server for Biology|February 6, 2026
The ancestral haplotype of P2RX5 yields a B-cell surface marker and a multi-lineage immunotherapy targetZhiwei Ang, Annette Castro, Luca Paruzzo, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|January 11, 2026
Clinical Trial Results Provide the Rationale to Protect Dual HIV-specific T Cells with a Signaling-Defective HIV Fusion InhibitorPablo Tebas, Julie K Jadlowsky, Yuqi Zhou, et al.
Nature Biotechnology|July 1, 2008
Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleasesElena E Perez, Jianbin Wang, Jeffrey C Miller, et al.
Nature Biomedical Engineering|October 21, 2025
CCR5-targeted allogeneic gamma-delta CD19 chimeric antigen receptor T cells for HIV-associated B cell-malignancy immunotherapyÁngel Ramírez-Fernández, Alexander J Dimitri, Fang Chen, et al.
Plos Pathogens|May 3, 2011
Engineering HIV-resistant human CD4+ T cells with CXCR4-specific zinc-finger nucleasesCraig B Wilen, Jianbin Wang, John C Tilton, et al.
The Journal of Clinical Investigation|February 11, 2021
CCR5-edited CD4+ T cells augment HIV-specific immunity to enable post-rebound control of HIV replicationPablo Tebas, Julie K Jadlowsky, Pamela A Shaw, et al.
Pageof 13